Stock Market Returns and Clinical Trial Results of Investigational Compounds: An Event Study Analysis of Large Biopharmaceutical Companies

Abstract

BackgroundFor biopharmaceutical companies, investments in research and development are risky, and the results from clinical trials are key inflection points in the process. Few studies have explored how and to what extent the public equity market values clinical trial results.MethodsOur study dataset matched announcements of clinical trial results for investigational compounds from January 2011 to May 2013 with daily stock market returns of large United States-listed pharmaceutical and biotechnology companies. Event study methodology was used to examine the relationship between clinical research events and changes in stock returns.ResultsWe identified public announcements for clinical trials of 24 investigational compounds, including 16 (67%) positive and 8 (33%) negative events. The majority of announcements were for Phase 3 clinical trials (N = 13, 54%), and for oncologic (N = 7, 29%) and neurologic (N = 6, 24%) indications. The median cumulative abnormal returns on the day of the announcement were 0.8% (95% confidence interval [CI]: –2.3, 13.4%; P = 0.02) for positive events and –2.0% (95% CI: –9.1, 0.7%; P = 0.04) for negative events, with statistically significant differences from zero. In the day immediately following the announcement, firms with positive events were associated with stock price corrections, with median cumulative abnormal returns falling to 0.4% (95% CI: –3.8, 12.3%; P = 0.33). For firms with negative announcements, the median cumulative abnormal returns were –1.7% (95% CI: –9.5, 1.0%; P = 0.03), and remained significantly negative over the two day event window. The magnitude of abnormal returns did not differ statistically by indication, by trial phase, or between biotechnology and pharmaceutical firms.ConclusionsThe release of clinical trial results is an economically significant event and has meaningful effects on market value for large biopharmaceutical companies. Stock return underperformance due to negative events is greater in magnitude and persists longer than abnormal returns due to positive events, suggesting asymmetric market reactions.

Pivotal clinical trials of novel ophthalmic drugs and medical devices: retrospective observational study, 2002–2012

“…Conducting pivotal trials is a time-intensive and resource-intensive process, 23 and the results from pivotal trials are important for patients and clinicians. In ophthalmology, as in other specialties, these data are often the principal source of information that patients and clinicians rely on to determine whether to use a newly approved therapeutic.…”

COVID 19: Effect on leading pharmaceutical stocks listed with NSE

“…Schumaker and Maida (2018) also came out with a similar conclusion by an example as the withdrawal of a popular drug from the product portfolio can result in declining the stock price of a pharma companies. According to Hwang (2013), 'Stock return underperformance due to negative events is greater in magnitude and persists longer than abnormal returns due to positive events'. In the context of our study, the unpleasant news of Covid 19 should positively hit pharmaceutical stocks.…”

Cautionary tales in the interpretation of observational studies of effects of clinical interventions

“…First, RCT have limitations regarding information value and generalisability of their results, [15][16][17] and may be very difficult to perform in certain situations (Table 3). [18][19][20][21][22][23][24][25][26] Some argue that their choice of questions and study design render many RCT clinically irrelevant. 27 They focus on assessing intervention efficacy under tightly controlled conditions rather than 'real-world' effectiveness.…”